Can-Fite BioPharma Conference Boosts Liver Cancer Study Enrollment
Ticker: CANF · Form: 6-K · Filed: May 13, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | May 13, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, press-release, oncology
TL;DR
Can-Fite BioPharma conference with 75 docs aims to speed up liver cancer drug trial enrollment.
AI Summary
On May 13, 2024, Can-Fite BioPharma Ltd. announced that 75 oncologists and coordinators from Europe, the US, and Israel participated in a conference focused on accelerating patient enrollment for their pivotal Phase 3 study of an advanced liver cancer treatment. This conference aims to speed up the process for the study, which is crucial for the drug's development.
Why It Matters
Accelerated patient enrollment in a Phase 3 trial is critical for advancing a new liver cancer treatment towards potential market approval, impacting future treatment options for patients.
Risk Assessment
Risk Level: medium — The filing reports on a conference to accelerate a Phase 3 trial, indicating progress but also the inherent risks and long timelines associated with late-stage drug development.
Key Numbers
- 75 — Participants (Number of oncologists and coordinators at the conference to accelerate patient enrollment for the Phase 3 liver cancer study.)
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant and subject of the press release
- May 13, 2024 (date) — Date of the press release
- 75 (number) — Number of oncologists and coordinators participating in the conference
- Europe, US, and Israel (location) — Geographic regions of participants
FAQ
What is the primary goal of the conference mentioned in the press release?
The primary goal of the conference was to accelerate patient enrollment for Can-Fite BioPharma's pivotal Phase 3 advanced liver cancer study.
Who participated in the conference?
75 oncologists and coordinators from Europe, the US, and Israel participated in the conference.
What specific study is being discussed?
The study being discussed is a pivotal Phase 3 study for an advanced liver cancer treatment.
On what date was the press release issued?
The press release was issued on May 13, 2024.
What is the company's ticker symbol?
The filing does not explicitly state the ticker symbol, but the company name is Can-Fite BioPharma Ltd.
Filing Stats: 212 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-05-13 07:03:28
Filing Documents
- ea0205893-6k_canfite.htm (6-K) — 9KB
- ea020589301ex99-1_canfite.htm (EX-99.1) — 13KB
- 0001213900-24-041896.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: May 13, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2